Literature DB >> 9028327

Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia.

C Selleri1, T Sato, L Del Vecchio, L Luciano, A J Barrett, B Rotoli, N S Young, J P Maciejewski.   

Abstract

Interferon-alpha (IFN-alpha) is an established treatment for chronic myelogenous leukemia (CML) in chronic phase, but the mechanism of its antileukemic activity is not clear. One possible mechanism of action might include the induction of apoptosis, and especially Fas-mediated cell killing may play an important role in the elimination of malignant cells. We investigated Fas receptor (Fas-R) expression and the consequences of Fas-R triggering in CML patients. Using two-color flow cytometry, we found a significantly higher number of Fas-R-expressing CD34+ cells in the bone marrow (BM) of CML patients compared with normal subjects. We have previously shown that IFN-gamma induces Fas-R expression on CD34+ cells; in this study, we investigated whether IFN-alpha induces Fas-R expression on CML progenitor cells. Dose-dependent induction of Fas-R expression was observed after IFN-alpha stimulation of CD34+ cells from CML BM. In methylcellulose culture, IFN-alpha alone at a therapeutic concentration showed only marginal antiproliferative effects on both normal and CML BM progenitors. In contrast, a Fas-R agonist, the anti-CD95 monoclonal antibody CH11, inhibited colony formation from normal progenitors, and the inhibition was even stronger on CML progenitors. When CML BM cells were cultured in the presence of IFN-alpha, Fas-R-mediated inhibition of colony growth was potentiated in a dose-dependent fashion, consistent with IFN-alpha induction of Fas-R expression. This functional effect did not require the presence of accessory cells, since similar results were obtained with purified CD34+ cells. In suspension cultures, we demonstrated that suppression of CML hematopoiesis by IFN-alpha and Fas-R agonist was exerted through Fas-R-mediated induction of apoptosis. Our findings suggest that the Fas-R/Fas-ligand system might be involved in the immunologic regulation of CML progenitor growth and that its effect can be amplified by IFN-alpha.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028327

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties.

Authors:  Anne Flörcken; Joachim Kopp; Uwe Kölsch; Christian Meisel; Bernd Dörken; Antonio Pezzutto; Jörg Westermann
Journal:  Hum Vaccin Immunother       Date:  2016-02-10       Impact factor: 3.452

2.  Antiviral treatment with alpha interferon up-regulates CD14 on liver macrophages and its soluble form in patients with chronic hepatitis B.

Authors:  Patrizia Carotenuto; Debby van Riel; André Artsen; Sven Bruijns; Fons G Uytdehaag; Jon D Laman; Andeltje B van Nunen; Pieter E Zondervan; Robert A De Man; Albert D Osterhaus; Oscar Pontesilli
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

3.  Molecular cloning and characterisation of the rock bream, Oplegnathus fasciatus, Fas (CD95/APO-1), and its expression analysis in response to bacterial or viral infection.

Authors:  Ji-Min Jeong; Ju-Won Kim; Hyoung-Jun Park; Jeong-Hun Song; Do-Hyung Kim; Chan-Il Park
Journal:  Results Immunol       Date:  2011-07-14

4.  Apoptosis in haematological malignancies.

Authors:  J A DiGiuseppe; M B Kastan
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

5.  Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.

Authors:  S X Hao; R Ren
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

6.  The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.

Authors:  Giuseppe Sconocchia; Michelle Lau; Maurizio Provenzano; Katayoun Rezvani; Wachanan Wongsena; Hiroshi Fujiwara; Nancy Hensel; Jos Melenhorst; Jonming Li; Soldano Ferrone; A John Barrett
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

7.  Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma.

Authors:  S Cavalheiro; P A Dastoli; N S Silva; S Toledo; H Lederman; M C da Silva
Journal:  Childs Nerv Syst       Date:  2005-06-14       Impact factor: 1.475

8.  Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.

Authors:  M Y Gordon; S B Marley; J L Lewis; R J Davidson; D X Nguyen; F H Grand; T A Amos; J M Goldman
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

9.  An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture.

Authors:  J J Cornelissen; R E Ploemacher; B W Wognum; A Borsboom; H C Kluin-Nelemans; A Hagemeijer; B Löwenberg
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

10.  Type I interferon induction is detrimental during infection with the Whipple's disease bacterium, Tropheryma whipplei.

Authors:  Khatoun Al Moussawi; Eric Ghigo; Ulrich Kalinke; Lena Alexopoulou; Jean-Louis Mege; Benoit Desnues
Journal:  PLoS Pathog       Date:  2010-01-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.